Feature | Carriers (+) | Â | Non-carriers (-) | p (95% CI) | OR |
---|---|---|---|---|---|
R160W | |||||
multiplicity1 | 3/852 (3.5%) | Â | 6/3743 (1.6%) | n.s. | 2.2 |
localization-skin4 | 2.45 | Â | 1.3 | n.s. | 1.8 |
tumour type6 | 607/208/109/410 | Â | 58/20/9/5 | n.s. | Â |
R151C | |||||
multiplicity | 3/73 (4.1%) | Â | 7/402 (1.7%) | n.s. | 2.4 |
localization in skin | 2.2 | Â | 1.4 | n.s. | 1.5 |
tumour type | 57/21/9/5 | Â | 54/19/10/6 | n.s. | Â |
V60L | |||||
multiplicity | 2/78 (2.6%) | Â | 6/355 (1.7%) | n.s. | 1.5 |
localization in skin | 2.0 | Â | 1.4 | n.s. | 1.4 |
tumour type | 58/22/11/4 | Â | 57/20/11/3 | n.s. | Â |
R163Q | |||||
multiplicity | 1/30 (3.3%) | Â | 8/355 (2.2%) | n.s. | 1.5 |
localization in skin | 1.9 | Â | 1.5 | n.s. | 1.3 |
tumour type | 60/19/10/5 | Â | 58/18/9/5 | n.s. | Â |
 | any of four variants positive |  | none of four variants positive |  |  |
multiplicity | 8/254 (3.1%) | Â | 1/149 (0.7%) | n.s. | 4.8 |
localization in skin | 2.2 |  | 1.0 | 0.0014 (1.35–3.63) | 2.2 |
tumour type | 61/21/8/5 | Â | 60/20/9/4 | n.s. | Â |